Established in 2004, Beijing Genovax Biotech Corporation ("Genovax") is located in the Peking University Bio-city of the prestigious Zhongguancun Science & Technology Zone.  Genovax is a high-tech biotechnology company that specializes in the research and development of protein/peptide and antibody drugs, gene therapy and vaccines, as well as Chinese herbal medicines and natural health products.  The company has a strong research team consisting of over 10 senior world-renowned scientists who have received Ph.D degrees and/or post-doctoral fellows from the world prestigious universities in United States and Canada with expertise in the field of cancer, neurodegenerative disease, virology, HIV/AIDs.

Genovax has established an independent Peptide Array platform including PEP-OVERLAP (Overlapping peptides from any protein sequence and Designing peptide array for a simple approach to mapping epitopes) and PEP-HIT (A powerful tool for identification of ligands which specifically recognize the target of interest through proprietary PEP-HIT data analysis software and high-throughput screening our proprietary epitomic peptide library) technologies. Genovax has successfully mapped all specific epitopes of SARS Corona Virus, and designed peptides which can effectively bind target proteins, including a peptide inhibiting reverse transcriptase of HIV, a key enzyme for HIV replication. This technology platform also makes possible to investigate pharmacological activities and mechanisms of action of Chinese herbal medicines/Natural medicines

Currently, Genovax has a diversity of R&D programs, and several drug candidates under development including PZ805 (one formula of active compounds for treating HIV/AIDS), and peptide inhibitors.  These peptide inhibitors can specifically interact with target proteins, such as P-GP, HIV-RT and Tau for the treating cancer, HIV/AIDS and Alzheimer's disease respectively. In addition, Based on the Peptide Array technology platform, Genovax will provide customized contract research and collaborative studies for biopharmaceutical, phytopharmaceutical and vaccine development companies and professionals locally in China as well as internationally in the world.

To date, Genovax has signed collaborative agreement with Beijing SinoBioway Group Co. of Peking University, China, as well as has sustained a close collaborative research partnership with many world-class universities and research institutes, such as the University of British Columbia (UBC) and BC Cancer Agency in Canada (BCCA), Fu Dan University, the Academy of Military Medical Sciences and Sino-Japanese Friendship Hospital in China.

Taking advantage of its proprietary Peptide Array Technology platform, and by collaborating with Chinese and international corporations and research institutes, Genovax is aiming to become a world-class biotechnology center for providing research and development of peptide/antibody drugs, Chinese herbal medicine and natural medicines.

Website: www.genovax.com